Blood-based biomarkers for Alzheimer's disease

Blood-based biomarkers for identifying Alzheimer's disease (AD) pathology have been of considerable interest over the past decade and can offer a significant advantage over the currently available and validated cerebrospinal fluid and positron emission tomography biomarkers in terms of cost, invasiveness and accessibility. This review explores the role of three blood-based biomarkers; plasma amyloid β, tau and neurofilament light chain, and their combination, in the identification of AD pathology and how they may be utilised in clinical practice.

Citation

Chohan, P., Dashwood, M., Theodoulou, G., Reed, H., & Kuruvilla, T. (2022). Blood-based biomarkers for Alzheimer's disease. Progress in Neurology and Psychiatry, 26(4), 10–14. https://doi.org/10.1002/pnp.764

DOI

10.1002/pnp.764

URI

https://hdl.handle.net/20.500.14709/587

Usage rights

Free access to article on publisher's webpage. Click DOI.